Porstendörfer J, Reineking A
Isotope Laboratory for Biological and Medical Research Georg-August-University, Göttingen, Germany.
Health Phys. 1999 Mar;76(3):300-5. doi: 10.1097/00004032-199903000-00011.
The dose conversion factor (DCF) which gives the relationship between effective dose and potential alpha energy concentration of inhaled short-lived radon decay products is calculated with a dosimetric approach. The calculations are based on a lung dose model with a structure that is related to the new recommended ICRP respiratory tract model. The characteristics of the radon decay products concerning the unattached fraction and the activity size distribution of the radon decay products are important input quantities for the calculation of DCF. Experimental data about these parameters obtained from measurements in homes, at working places, and in the free atmosphere at ground level in the last past years are summarized. Taking into account the measured aerosol characteristics the DCF fractions of the unattached (DCFu) and aerosol-attached (DCFae) radon decay products for different places were calculated. Variation of DCF for different places were caused dominantly by the variation of DCFu of the unattached radon clusters (0.3-32 mSv WLM(-1)). Nose inhalation drastically reduced (about a factor 4) the dose contribution by the unattached cluster. The dose fraction by the radon decay product aerosol (DCFae) varies between 4-10 mSv WLM(-1). Taking into account a relative sensitivity distribution between bronchial, bronchiolar and alveolar regions of the thoracic lung with 0.80:0.15:0.05 and nose breathing the DCF of most of the working places (inhalation rate: 1.2 m3 h(-1)) vary between 5.7-6.7 mSv WLM(-1) depending on the number concentration of the aerosol particles. The DCF-value of 4.2 mSv WLM(-1) for the general public in dwellings with higher aerosol concentration (>4 x 10(4) particles cm(-3)) has about the same value as recommended by ICRP 65 (1994b). Significantly higher are the DCF-values for "normal" aerosol conditions indoors (5 x 10(3)-4 x 10(4) particles cm(-3)) and in the open air (7.3 mSv WLM(-1) and 9.7 mSv WLM(-1)).
剂量转换因子(DCF)给出了吸入短寿命氡衰变产物的有效剂量与潜在α能量浓度之间的关系,它是通过剂量学方法计算得出的。这些计算基于一个肺部剂量模型,该模型的结构与国际辐射防护委员会(ICRP)新推荐的呼吸道模型相关。氡衰变产物的未附着部分以及氡衰变产物的活度大小分布等特性,是计算DCF的重要输入量。本文总结了过去几年在家庭、工作场所和地面自由大气中测量得到的关于这些参数的实验数据。考虑到测量得到的气溶胶特性,计算了不同场所未附着(DCFu)和气溶胶附着(DCFae)的氡衰变产物的DCF分数。不同场所DCF的变化主要是由未附着氡簇的DCFu变化(0.3 - 32 mSv WLM⁻¹)引起的。经鼻腔吸入可大幅降低(约4倍)未附着簇的剂量贡献。氡衰变产物气溶胶的剂量分数(DCFae)在4 - 10 mSv WLM⁻¹之间变化。考虑到胸部肺部支气管、细支气管和肺泡区域之间的相对敏感度分布为0.80:0.15:0.05以及经鼻腔呼吸,大多数工作场所(吸入率:1.2 m³ h⁻¹)的DCF根据气溶胶颗粒的数量浓度在5.7 - 6.7 mSv WLM⁻¹之间变化。对于气溶胶浓度较高(>4×10⁴颗粒 cm⁻³)的住宅中的普通公众,DCF值为4.2 mSv WLM⁻¹,与ICRP 65(1994b)推荐的值大致相同。在室内“正常”气溶胶条件(5×10³ - 4×10⁴颗粒 cm⁻³)和露天环境下,DCF值明显更高(分别为7.3 mSv WLM⁻¹和9.7 mSv WLM⁻¹)。